# Wave Life Sciences (WVE) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/WVE
## Company Profile
- Ticker: WVE
- Exchange: NASDAQ
- Sector: Life Science Tools
- Location: United States
- Tags: Life Science Tools
## Stock Data
- Close: 5.24 USD
- Market cap: 1094768529.38 USD
- Last updated: 2026-08-12
## Business Overview
### RNA Medicines Platform Company
Wave Life Sciences is a clinical-stage biotechnology company developing RNA medicines across both rare and common diseases. Its PRISM platform combines RNA-targeting modalities, chemistry innovation, and human genetics to design medicines that can address disease biology through RNAi and RNA editing.
### Obesity and Cardiometabolic Program
WVE-007 is an investigational GalNAc-siRNA targeting INHBE for obesity and related cardiometabolic disease. The program is designed to induce fat loss without muscle loss and is distinct from incretin-based approaches. Phase 1 data have shown fat reduction, visceral fat reduction, waist-circumference effects, and muscle preservation, supporting evaluation in higher-BMI populations and broader metabolic settings.
### RNA Editing in Liver and Rare Disease
WVE-006 is a GalNAc-conjugated RNA editing oligonucleotide for alpha-1 antitrypsin deficiency. Clinical data from RestorAATion-2 support the potential to address both lung and liver manifestations by reducing mutant Z-AAT protein and increasing wild-type M-AAT protein. WVE-008 extends the RNA editing approach into PNPLA3 I148M liver disease.
### Strategic Position
Wave is best understood as an RNA medicines company trying to prove that its chemistry and modality breadth can support both high-prevalence diseases such as obesity and genetically defined liver diseases. Its value depends on clinical translation across WVE-007, WVE-006, and WVE-008, with additional optionality in Huntington's disease and Duchenne muscular dystrophy.
## Why The Stock Is Moving

As of Aug 12, 2026, WVE closed up 3.87% at $5.24. No new same-company headline was identified in the current news window.

## Future Catalysts

- Additional Phase 1 INLIGHT data for WVE-007 in the second half of 2026.
- Phase 2a multidose INLIGHT data over the 12-month assessment period.
- Initiation of WVE-007 Phase 2 trials in incretin combination and post-incretin maintenance settings in the second half of 2026.
- FDA meeting on a potential accelerated approval pathway for WVE-006 by the end of summer 2026.
- WVE-006 600 mg monthly multidose data in the second half of 2026.
- CTA filing for WVE-008 in PNPLA3 liver disease in the second half of 2026.

## Recent News
- 2026-08-10 12:30 EST — [Wave Life Sciences Announces Completion of Redomiciliation to Delaware](https://biopharmsignal.com/news/WVE/wave-life-sciences-announces-completion-of-redomiciliation-to-delaware-e78d7803) — Source: Wave Life Sciences
- 2026-08-05 20:05 EST — [Wave Life Sciences Announces Expected Completion Date for Redomiciliation to Delaware](https://biopharmsignal.com/news/WVE/wave-life-sciences-announces-expected-completion-date-for-redomiciliation-to-del-79de9580) — Source: Wave Life Sciences
- 2026-07-30 11:30 EST — [Wave Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/WVE/wave-life-sciences-reports-second-quarter-2026-financial-results-and-provides-bu-ce5af4f7) — Source: Wave Life Sciences
- 2026-07-23 12:30 EST — [Wave Life Sciences Second Quarter 2026 Financial Results Scheduled for July 30, 2026](https://biopharmsignal.com/news/WVE/wave-life-sciences-second-quarter-2026-financial-results-scheduled-for-july-30-2-a9974bb9) — Source: Wave Life Sciences
- 2026-07-07 20:15 EST — [Wave Life Sciences Announces Singapore Court Hearing, to be held on July 14, 2026 to Approve Scheme of Arrangement for Redomiciliation](https://biopharmsignal.com/news/WVE/wave-life-sciences-announces-singapore-court-hearing-to-be-held-on-july-14-2026--d94f52e6) — Source: Wave Life Sciences